SecBot SecBot

KPRX

KIORA PHARMACEUTICALS INC
Nasdaq· Pharmaceutical Preparations· CIK 0001372514 Biotech & Drug Discovery
$2.28 −0.01 (−0.44%)
Oct 26 4:00 PM ET · prev $2.29
Market cap
$10.3M
Nano cap
Median target
$12.00
+426% · range $12.00–12.00
Next earnings
Nov 5
in 10 days · EPS est. −$0.38
1 year
−9.9%
from $2.53 · Oct 27
30 days
−14.6%
from $2.67
52-week range
$1.80–2.86
−20% from high · low Nov 20
Avg volume 20D
13.1K
shares / day
Short interest
3.4K
≈0.1% of shares · −14.6%
Days to cover
1.0
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
4
analyzed by SecBot
SecBot read BULLISH 3 reports · 90 days
Balance 0 bearish · 1 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 3/3 ·Next Earnings date, Nov 5, 2026
Strongest BULLISH Kiora Pharmaceuticals has entered into an exclusive license agreement with Chong Kun Dang Pharmaceutical…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

  • X Jul 31 Short interest falls 53.5% to 3.9K

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q2 2026: 2 added (0 new), 1 trimmed or exited.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.690 → −$0.380 over 90 days. 1 up, 0 down in 30 days.

  • Short sellersSTEADY

    Short interest −14.6% to 3.4K shares. 1.0 days to cover, ≈0.1% of shares.

  • TrendDOWNTREND

    11% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
CITADEL ADVISORS LLCDOUBLED116,011$305.1K
GEODE CAPITAL MANAGEMENT, LLCTRIM26,717$70.3K
UBS Group AGADD1,961$5.2K
GEODE CAPITAL MANAGEMENT, LLCDOUBLED47,850$92.3K
UBS Group AGADD1,301$2.5K
VANGUARD GROUP INCADD33,091$65.2K
RENAISSANCE TECHNOLOGIES LLCADD21,200$41.8K
UBS Group AGTRIM912$1.8K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Sep 2025
12-month targets · 1 analysts

Price is below the lowest target. Median implies +426%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Sep 2, 2025HC Wainwright & Co.
REITERATE
REITERATEBuy
Mar 28, 2025HC Wainwright & Co.
REITERATE
REITERATEBuy
Nov 12, 2024HC Wainwright & Co.
REITERATE
REITERATEBuy
Aug 22, 2024HC Wainwright & Co.
REITERATE
REITERATEBuy
Jul 23, 2024HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
May 20, 2024HC Wainwright & Co.
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Sep 17, 2026
Lane Keith J.
AWARD55,000 sh
Jul 1, 2026
Strem Brian M.
President and CEO
TAX W/H$5.0K
Jul 1, 2026
Tosca Melissa
CFO
TAX W/H$2.4K
Jun 10, 2026
TYLE PRAVEEN
Director
AWARD40,000 sh
Jun 10, 2026
Parsons Erin
Director
AWARD25,000 sh
Jun 10, 2026
Shapiro Aron
Director
AWARD25,000 sh
Jun 10, 2026
Hollander David
Director
AWARD25,000 sh
Jun 10, 2026
Stengone Carmine N.
Director
AWARD25,000 sh

Earnings setup

Estimates
Nov 5
reports in 10 days
−$0.38
EPS estimate, this quarter
+45%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.38-$0.38–-$0.38+44.9%$0.00
Next Q-$0.42-$0.42–-$0.42+44.7%$0.00
Current FY-$1.67-$1.67–-$1.67+37.2%$0.00
Next FY-$1.41-$1.41–-$1.41+28.4%$0.00

Short side

FINRA· Sep 30, 2026
3,432
shares short
-14.6%
vs prior settlement
1.0
days to cover
≈0.1%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 17, 2026 Insider
Lane Keith J. was granted 55,000 shares
Sep 8, 2026 SEC
Kiora Pharmaceuticals appointed Keith Lane as Executive Vice President, Head of Clinical Development and Regulatory…
8-K — Impact 3/10
Aug 19, 2026 SEC
Kiora Pharmaceuticals has entered into an exclusive license agreement with Chong Kun Dang Pharmaceutical (CKD) for the…
8-K — Impact 5/10
Aug 7, 2026 SEC
Kiora Pharmaceuticals reported Q2 2026 net loss of $2.1M ($0.34 per share), improved from $2.2M ($0.54) in Q2 2025…
8-K — Impact 4/10
Aug 6, 2026 Earnings calendar
KPRX Q2 2026 Earnings Scheduled — 2026-08-06
Jul 1, 2026 Insider
Strem Brian M. surrendered for taxes 1,869 shares
President and CEO @ $2.66 ($5.0K)
Jul 1, 2026 Insider
Tosca Melissa surrendered for taxes 911 shares
CFO @ $2.66 ($2.4K)
Jun 30, 2026 Inst.
CITADEL ADVISORS LLC — DOUBLED
116,011 shares ($305.1K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 5, 2026
Earnings date
KPRX Q3 2026 Earnings Scheduled — 2026-11-05
Recent
Aug 6, 2026
Earnings date
KPRX Q2 2026 Earnings Scheduled — 2026-08-06
May 7, 2026
Earnings date
KPRX Q1 2026 Earnings Scheduled — 2026-05-07
May 4, 2026
Clinical Trial
A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS)
Phase 2 · COMPLETED
Mar 23, 2026
Earnings date
KPRX Q4 2025 Earnings After Market Close — 2026-03-23

SecBot reports

4 filings · 2 bullish · 0 bearish · 2 neutral
All KPRX filing & press-release reports (4)